174 related articles for article (PubMed ID: 21481181)
21. In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.
Leblond L; Grouix B; Boudreau C; Yang Q; Siddiqui MA; Winocour PD
Thromb Res; 2000 Nov; 100(3):195-209. PubMed ID: 11108907
[TBL] [Abstract][Full Text] [Related]
22. Dabigatran etexilate: a new thrombin inhibitor.
Verma AK
Med J Aust; 2010 Apr; 192(7):407-12. PubMed ID: 20367591
[TBL] [Abstract][Full Text] [Related]
23. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
[TBL] [Abstract][Full Text] [Related]
24. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.
Watanabe M; Siddiqui FM; Qureshi AI
Neurocrit Care; 2012 Feb; 16(1):203-9. PubMed ID: 21748501
[TBL] [Abstract][Full Text] [Related]
25. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Siddiqui FM; Qureshi AI
Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
[TBL] [Abstract][Full Text] [Related]
26. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.
Gulseth MP; Wittkowsky AK; Fanikos J; Spinler SA; Dager WE; Nutescu EA
Pharmacotherapy; 2011 Dec; 31(12):1232-49. PubMed ID: 22122184
[TBL] [Abstract][Full Text] [Related]
27. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
28. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.
Liesenfeld KH; Schäfer HG; Trocóniz IF; Tillmann C; Eriksson BI; Stangier J
Br J Clin Pharmacol; 2006 Nov; 62(5):527-37. PubMed ID: 17061960
[TBL] [Abstract][Full Text] [Related]
29. New therapeutic option for thromboembolism--dabigatran etexilate.
Nishio H; Ieko M; Nakabayashi T
Expert Opin Pharmacother; 2008 Oct; 9(14):2509-17. PubMed ID: 18778188
[TBL] [Abstract][Full Text] [Related]
30. The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis.
McClanahan TB; Hicks GW; Ignasiak DP; Bousley R; Mertz TE; Juneau P; Janiczek-Dolphin N; Kim IC; Gallagher KP
J Thromb Thrombolysis; 2000 Dec; 10(3):277-84. PubMed ID: 11122549
[TBL] [Abstract][Full Text] [Related]
31. Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ; Gardell SJ; Holahan MA; Sitko GR; Stump GL; Wallace AA; Gilberto DB; Hare TR; Krueger JA; Dyer DL; Sanderson PE; Vacca JP; Shafer JA; Lynch JJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):503-10. PubMed ID: 10087043
[TBL] [Abstract][Full Text] [Related]
32. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Peternel L; Stegnar M; Drevensek G; Budihna MV; Bozic M; Zega A; Stalc A; Cerne M; Urleb U
Thromb Haemost; 2005 Mar; 93(3):437-42. PubMed ID: 15735792
[TBL] [Abstract][Full Text] [Related]
33. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Eriksson BI; Dahl OE; Büller HR; Hettiarachchi R; Rosencher N; Bravo ML; Ahnfelt L; Piovella F; Stangier J; Kälebo P; Reilly P;
J Thromb Haemost; 2005 Jan; 3(1):103-11. PubMed ID: 15634273
[TBL] [Abstract][Full Text] [Related]
34. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Garnock-Jones KP
Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
McKellar SH; Abel S; Camp CL; Suri RM; Ereth MH; Schaff HV
J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1410-6. PubMed ID: 21429525
[TBL] [Abstract][Full Text] [Related]
36. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
Ma TK; Yan BP; Lam YY
Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
[TBL] [Abstract][Full Text] [Related]
37. Dabigatran etexilate: future directions in anticoagulant treatment.
Schulman S; Reilly PA
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
[TBL] [Abstract][Full Text] [Related]
38. The effect of dabigatran on select specialty coagulation assays.
Adcock DM; Gosselin R; Kitchen S; Dwyre DM
Am J Clin Pathol; 2013 Jan; 139(1):102-9. PubMed ID: 23270905
[TBL] [Abstract][Full Text] [Related]
39. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
McClanahan TB; Hicks GW; Morrison AL; Peng YW; Janiczek-Dolphin N; Mertz TE; Sullivan ME; Morser J; Juneau PL; Leadley R
Eur J Pharmacol; 2001 Dec; 432(2-3):187-94. PubMed ID: 11740955
[TBL] [Abstract][Full Text] [Related]
40. Evaluating antithrombotic activity of HY023016 on rat hypercoagulable model.
Chen QF; Li YZ; Wang XH; Su YR; Cui S; Miao MX; Jiang ZZ; Jiang ML; Jiang AD; Chen X; Xu YG; Gong GQ
Eur J Pharmacol; 2016 Jun; 781():190-7. PubMed ID: 27085896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
